Zenotech Laboratories
- Market cap
- ₹ 244 Cr.
- P/E
- 408.7x
- P/B
- 2.53x
- 52-week range
- 33.55 – 54.14
- ROE
- −1%
- ROCE
- 4.6%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Zenotech Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in a business of manufacture and marketing of pharmaceuticals products. The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing oncology, biotechnology and general injectables products. The Company’s injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. Its product includes granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The Company has a manufacturing facility at Turkapally village, Shamirpet Mandal, Telangana.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Zenotech Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)408.7 against a typical 34.3: pricier than most peers (1st = cheapest).214th of 220
- Sales growth+10.2% against a typical +15.6% from a year earlier.114th of 197
- Profit growth−146.5% against a typical +18.9% from a year earlier.153rd of 160
- Share price, 3 months−14.5% against a typical 0%.165th of 200
- Size₹ 244.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).113th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 11 | 9 | 10 | 10 | 11 | 12 | 10 | 11 | 13 | 10 | 11 |
| Expenses | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 9 | 9 | 10 | 10 |
| Operating Profit | 6 | 5 | 3 | 3 | 2 | 4 | 4 | 2 | 2 | 4 | 0 | 1 |
| OPM % | 47.9% | 48.2% | 30.5% | 34.6% | 24.7% | 34.4% | 36.9% | 25.5% | 20.4% | 33.2% | 1.7% | 8.1% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 4 | 4 | 1 | 2 | 2 | 3 | 3 | 1 | 1 | 3 | −1 | −1 |
| Tax % | 27.2% | 11.6% | 51.5% | 37.3% | 42.6% | 45.7% | 61.3% | 22.7% | 165.9% | 25.5% | 235.1% | −25% |
| Net Profit | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | −1 | 2 | −3 | −0 |
| EPS in Rs | 0.46 | 0.55 | 0.11 | 0.21 | 0.22 | 0.28 | 0.2 | 0.16 | −0.14 | 0.32 | −0.52 | −0.08 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 36%
- 5 Years
- 14%
- 3 Years
- 1%
- TTM
- 4%
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- —
- TTM
- −150%
- 10 Years
- 2%
- 5 Years
- −2%
- 3 Years
- −4%
- TTM
- —
- 10 Years
- —
- 5 Years
- 11%
- 3 Years
- 4%
- TTM
- —
Peers
Listed companies in the same business.
| Zenotech Laboratories | ₹ 37.99 | ₹ 244 Cr. | 408.7x | 2.5x | −1% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sachin Laxmanappa Gavandare
- Chief Executive Officer
- K.V. Poly
- Chief Financial Officer
- Abdul Gafoor Mohammad
- Chief Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.